Digest Network Come funziona
Network
/
Società
Te
Non verificato

Teva Pharmaceutical Industries Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceuticaFinanzaManagement/Organizzazione AziendaleMedicina Salute Benessere

89 comunicati stampa

Guarda tutti i comunicati
03/03/2026
Farmaceutica
Finanza
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
24/02/2026
Farmaceutica
Teva to Present at the Upcoming Investor Conferences in March
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
20/02/2026
Farmaceutica
Annunci Economici
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
17/02/2026
Farmaceutica
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
28/01/2026
Farmaceutica
Management/Organizzazione Aziendale
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
27/01/2026
Farmaceutica
Medicina Salute Benessere
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
14/01/2026
Farmaceutica
Medicina Salute Benessere
Annunci Economici
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
11/01/2026
Farmaceutica
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
11/01/2026
Farmaceutica
Medicina Salute Benessere
Management/Organizzazione Aziendale
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0
05/01/2026
Farmaceutica
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fonte
Teva Pharmaceutical Industries Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0